-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Atara Biotherapeutics said Friday that a phase I trial of its autologous mesothelin-targeted CAR-T cell therapy ATA2271 has been suspended due to fatal serious adverse events (SAEs) in participants treated in the study.
.
The experimental therapy is currently in clinical studies in patients with malignant pleural mesothelioma
CAR-T
The MSK Phase I clinical study enrolled 27 patients, 25 with malignant pleural mesothelioma (MPM), 1 with metastatic lung cancer , and 1 with metastatic breast cancer , who had received 3 prior treatment regimens , The purpose of this study was to evaluate the safety and potential antitumor activity of mesothelin-targeted autologous CAR-T cell therapy
.
The study added two higher-dose cohorts, administered directly to the tumor site, to the 6-dose cohort reported in March 2019
lung cancer breast cancer
Pleural mesothelioma (MPM) is a primary tumor derived from pleural mesothelial cells and accounts for 5% of pleural tumors
.
Pleural mesothelioma can occur in any part of the visceral and parietal pleura, with 80% occurring in the visceral pleura and 20% in the parietal pleura
According to Atara, the deceased had a history of multiple malignancies and other comorbidities, and the patient was being treated for advanced, recurrent mesothelioma
.
The first six participants in the trial's two lowest-dose cohorts received either 1x106 cells/kg or 3x106 cells/kg intrapleural ATA2271 and there were no dose-limiting toxicities, the
6 6 According to Atara, the patient who died was the first patient to receive the high-dose cohort of 6x10 6 cells/kg
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/4801745 https://firstwordpharma.
com/story/4801745 Leave a comment here
